share_log

RedHill Settles Movantik Patent Litigation With Aurobindo

Benzinga Real-time News ·  2021/09/23 11:11
  • RedHill Biopharma Ltd (NASDAQ:RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S.
  • The litigation was related to Aurobindo's Abbreviated New Drug Application seeking approval by the FDA to market a generic version of Movantik (naloxegol).
  • RedHill acquired from AstraZeneca plc (NASDAQ:AZN) in April 2020 the global rights to Movantik, excluding Europe and Canada.
  • Under the settlement agreement terms, Aurobindo may not sell a generic version of Movantik in the U.S. until April 1, 2031.
  • Related: RedHill Unveils New Movantik Data For Opioid-Induced Constipation.
  • Price Action: RDHL stock is up 0.21% at $4.76 during the market session on the last check Thursday.
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする